NCT04011475

A Study in Taiwan Based on Medical Records That Looks at the Occurrence of Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Started LABA/LAMA or LAMA Treatment

Taiwan Outcomes and Real-world Treatment Options for Chronic Obstructive Pulmonary Disease

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 1,617 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

Study to collect the data on Chronic Obstructive Pulmonary Disease (COPD) patients who were administered with Long-Acting Beta-Agonist/ Long-Acting Muscarinic Antagonist (LABA/LAMA) (Fixed-dose Combination (FDC) or free combo) or LAMA treatment

Conditions

• Pulmonary Disease, Chronic Obstructive

Interventions

Type	Name	Description
DRUG	Tiotropium + Olodaterol	Spiolto®
DRUG	Other LABA/LAMA	tiotropium/olodaterol, indacaterol/glycopyrronium, vilanterol/umeclidinium
DRUG	LAMA	aclidinium bromide, glycopyrronium, tiotropium, umeclidinium

Timeline

• Start date: 2019-12-29
• Primary completion: 2020-10-31
• Completion: 2020-10-31
• First posted: 2019-07-08
• Last updated: 2022-06-14
• Results posted: 2022-03-11

Locations

12 sites across 1 country: Taiwan

Regulatory

• FDA-regulated drug study